Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T13:30:32.683Z.
Calculation as of: 2026-10-06T13:30:32.683Z.
Quote observation: 2026-10-06T13:30:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9a6fb48ec682e3cf9a2a3de0b7f1962f0667ac92b413acd908fc1cfb112ec24a
PEG RATIO
N/A
Apollomics, Inc.
Market Cap
$51.17M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Apollomics, Inc. (APLM) | $51.17M | N/A |
| Envoy Medical, Inc. (COCH)vs › | $51.72M | N/A |
| Clene Inc. (CLNN)vs › | $49.84M | N/A |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $52.80M | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | N/A |
| Celularity Inc. (CELU)vs › | $49.21M | N/A |
| INmune Bio, Inc. (INMB)vs › | $51.84M | N/A |
| biote Corp. (BTMD)vs › | $49.40M | N/A |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $52.71M | N/A |
| ImageneBio Inc (IMA)vs › | $53.01M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
